Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists

References

• Andersson BS, Kashyap A, Couriel D, Madden T, de Lima M, Thall PF, Fernandez H, Vaughan WP, Jones R, Wingard JR, Blume KG, Champlin RE. Intravenous busulfan in pretransplant chemotherapy: Bioavailability and patient benefit. Biology of Blood Marrow Transplantation 2003; 9: 722–724
   PubMed Web of Science ®Google Scholar
• Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M. Stealth Me.PEG-PLA nanoparticules avoid uptake by the mononuclear phagocytes system. Journal of Pharmaceutical Sciences 1995; 84: 493–498
   PubMed Web of Science ®Google Scholar
• Bedford P, Fox BW. Repair of DNA interstrand crosslinks after busulphan. A possible mode of resistance. Cancer, Chemotherapy and Pharmacology 1982; 8: 3–7
   PubMed Web of Science ®Google Scholar
• Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer, Chemotherapy and Pharmacology 1996; 37: 401–408
   PubMed Web of Science ®Google Scholar
• Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O, Vassal G. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplantation 2003; 32: 979–986
   PubMed Web of Science ®Google Scholar
• Bouligand J, Paci A, Mercier L, Vassal G, Bourget P. High-performance thin-layer chromatography with a derivatization procedure, a suitable method for the identification and the quantitation of busulfan in various pharmaceutical products. Journal of Pharmaceutics and Biomedicine Analysis 2004; 34: 525–530
   PubMedGoogle Scholar
• Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: A new frontier in cancer chemotherapy. Tumori 2003; 89: 237–249
   PubMed Web of Science ®Google Scholar
• Chow AHL, Chow PKK, Zhuang J, Groen AK. Modification of acetaminophen crystals: Influence of growth in aqueous solutions containig of growth in aqueous solutions containig p-acetoxyacetanilide on crystal properties. International Journal of Pharmaceutics 1985; 24: 239–258
   Web of Science ®Google Scholar
• Chow KY, Go J, Mehdizadeh M, Groen AK. Modification of adipic crystals: Influence of growth in the presence of fatty acid additives on crystals properties. International Journal of Pharmaceutics 1984; 20: 3–24
   Web of Science ®Google Scholar
• Dalle JH, Wall D, Theoret Y, Duval M, Shaw L, Larocque D, Taylor C, Gardiner J, Vachon MF, Champagne MA. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: Clinical and pharmacokinetic results. Bone Marrow Transplantation 2003; 32: 647–651
   PubMed Web of Science ®Google Scholar
• DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 2000; 60: 143–154
   PubMed Web of Science ®Google Scholar
• Dunn CD. The chemical and biological properties of busulphan (‘Myleran’). Experimental Hematology 1974; 2: 101–117
   PubMed Web of Science ®Google Scholar
• Ehrsson H, Hassan M. Degradation of busulfan in aqueous solution. Journal of Pharmaceutics and Biomedical Analysis 1986; 4: 95–101
   PubMedGoogle Scholar
• Ghermani NE, Spasojevic-de Bire A, Bouhmaida N, Ouharzoune S, Bouligand J, Layre A, Gref R, Couvreur P. Molecular reactivity of busulfan through its experimental electrostatic properties in the solid state. Pharmaceutical Research 2004; 21: 598–607
   PubMedGoogle Scholar
• Gref R, Domb A, Quellec P, Blunk T, Muller RH, Verbavatz JM, Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Advanced Drug Delivery Reviews 1995; 16: 215–233
   PubMed Web of Science ®Google Scholar
• Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH. ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids and Surfactants B: Biointerfaces 2000; 18: 301–313
   PubMed Web of Science ®Google Scholar
• Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263: 1600–1603
   PubMed Web of Science ®Google Scholar
• Grover PK, Moritz RL, Simpson RJ, Ryall RL. Inhibition of growth and aggregation of calcium oxalate crystals in vitro—a comparison of four human proteins. European Journal of Biochemistry 1998; 253: 637–644
   PubMedGoogle Scholar
• Hartmann O, Benhamou E, Beaujean F, Pico JL, Kalifa C, Patte C, Flamant F, Lemerle J. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: A phase II study. Journal of Clinical Oncology 1986; 4: 1804–1810
   PubMed Web of Science ®Google Scholar
• Hassan M, Ehrsson H, Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leukemia and Lymphoma 1996; 22: 395–407
   PubMed Web of Science ®Google Scholar
• Hassan M, Hassan Z, Nilsson C, Rehim MA, Kumlien S, Elfsson B, Kallberg N. Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. Cancer, Chemotherapy and Pharmacology 1998a; 42: 471–478
   PubMed Web of Science ®Google Scholar
• Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, Stary J, Wallin I, Kallberg N. Busulfan bioavailability. Blood 1994; 84: 2144–2150
   PubMed Web of Science ®Google Scholar
• Hassan M, Nilsson C, Hassan Z, Gungor T, Aschan J, Winiarski J, Hentschke P, Ringden O, Eber S, Seger R, Ljungman P. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. Bone Marrow Transplantation 2002; 30: 833–841
   PubMed Web of Science ®Google Scholar
• Hassan Z, Ljungman P, Ringden O, Winiarski J, Nilsson C, Aschan J, Whitley HR, Hassan M. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplantation 2001; 27: 479–485
   PubMedGoogle Scholar
• Hassan Z, Nilsson C, Hassan M. Liposomal busulphan: bioavailability and effect on bone marrow in mice. Bone Marrow Transplantation 1998b; 22: 913–918
   PubMedGoogle Scholar
• Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, Blume K, Niland J, Palmer JM, Vaughan W, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biology of Blood Marrow Transplantation 2002; 8: 493–500
   PubMed Web of Science ®Google Scholar
• Layre A, Couvreur P, Chacun H, Richard J, Passirani C, Requier D, Benoit JP, Gref R. Novel composite core-shell nanoparticles as busulfan carriers. Journal of Controlled Release 2006a; 111: 271–280
   PubMed Web of Science ®Google Scholar
• Layre AM, Couvreur P, Chacun H, Aymes-Chodur C, Ghermani NE, Poupaert J, Richard J, Requier D, Gref R. Busulfan loading into poly(alkyl cyanoacrylate) nanoparticles: Physico-chemistry and molecular modeling. Journal of Biomedical Materials Research B: Applied Biomaterials 2006b; 79: 254–262
   PubMedGoogle Scholar
• Layre AM, Gref R, Richard J, Requier D, Chacun H, Appel M, Domb AJ, Couvreur P. Nanoencapsulation of a crystalline drug. International. Journal of Pharmaceutics 2005; 298: 323–327
   PubMed Web of Science ®Google Scholar
• McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Annals of Internal Medicine 1993; 118: 255–267
   PubMed Web of Science ®Google Scholar
• Meresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L, Lemerle J. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study in 136 children. Bone Marrow Transplantation 1992; 10: 135–141
   PubMed Web of Science ®Google Scholar
• Montet JC, Parquet M, Sacquet E, Montet AM, Infante R, Amic J. beta-Muricholic acid; potentiometric and cholesterol-dissolving properties. Biochimica et Biophysica Acta 1987; 918: 1–10
   PubMedGoogle Scholar
• Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: A novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplantation 2004; 33: 979–987
   PubMed Web of Science ®Google Scholar
• Nikolakakis I, Kachrimanis K, Malamataris S. Relations between crystallisation conditions and micromeritic properties of ibuprofen. International Journal of Pharmaceutics 2000; 201: 79–88
   PubMed Web of Science ®Google Scholar
• Olavarria E, Hassan M, Eades A, Nilsson C, Timms A, Matthews J, Craddock C, Kanfer E, Apperley J, Goldman J. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation [In Process Citation]. Leukemia 2000; 14: 1954–1959
   PubMedGoogle Scholar
• Raghavan SL, Trividic A, Davis AF, Hadgraft J. Crystallization of hydrocortisone acetate: Influence of polymers. International Journal of Pharmaceutics 2001; 212: 213–221
   PubMed Web of Science ®Google Scholar
• Santos GW. The development of busulfan/cyclophosphamide preparative regimens. Seminars in Oncology 1993; 20: 12–16
   PubMed Web of Science ®Google Scholar
• Schott H, Royce AE. Effect of nonionic surfactants on aqueous primidone suspensions. Journal of Pharmaceutical Sciences 1985; 74: 957–962
   PubMed Web of Science ®Google Scholar
• Schuler US, Ehrsam M, Schneider A, Schmidt H, Deeg J, Ehninger G. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplantation 1998; 22: 241–244
   PubMed Web of Science ®Google Scholar
• Schuler US, Renner UD, Kroschinsky F, Johne C, Jenke A, Naumann R, Bornhauser M, Deeg HJ, Ehninger G. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. British Journal of Haematology 2001; 114: 944–950
   PubMed Web of Science ®Google Scholar
• Shirane Y, Kurokawa Y, Miyashita S, Komatsu H, Kagawa S. Study of inhibition mechanisms of glycosaminoglycans on calcium oxalate monohydrate crystals by atomic force microscopy. Urology Research 1999; 27: 426–431
   PubMedGoogle Scholar
• Tazuma S, Sasaki H, Mizuno S, Sagawa H, Hashiba S, Horiuchi I, Kajiyama G. Effect of ursodeoxycholic acid administration on nucleation time in human gallbladder bile. Gastroenterology 1989; 97: 173–178
   PubMed Web of Science ®Google Scholar
• Usui F, Maeda K, Kusai A, Nishimura K, Yamamoto K. Inhibitory effects of water-soluble polymers on precipitation of RS-8359. International Journal of Pharmaceutics 1997; 154: 59–66
   Web of Science ®Google Scholar
• Vassal G, Re M, Gouyette A. Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard. Journal of Chromatography 1988; 428: 357–361
   PubMed Web of Science ®Google Scholar
• Westerhof GR, Ploemacher RE, Boudewijn A, Blokland I, Dillingh JH, McGown AT, Hadfield JA, Dawson MJ, Down JD. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Research 2000; 60: 5470–5478
   PubMed Web of Science ®Google Scholar